MHC-I presents peptides derived from endogenous antigens. Antigen is proteolyzed by the immune proteasome and specific peptides loaded to MHC-I. The resulting MHC-I–peptide complex is transported to ...

TACTI-004 trial evaluates efti with Keytruda and chemotherapy for advanced NSCLC, focusing on progression-free and overall survival. Efti's unique MHC Class 2 agonist mechanism shows strong efficacy ...

Our core provides customized MHC/peptide tetramers for identification of antigen-specific T lymphocytes by flow cytometry. Tetramers and/or their derivatives are provided for research purposes only.

Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies for immunologically cold cancers, today announced two poster presentations at the American ...

Disparities in trends in bladder cancer mortality between urban and rural patients: A 2000-2020 analysis. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...